Re: Rethinking neoadjuvant chemotherapy for breast cancer
This study aims to analyse trends in the use of neoadjuvant chemotherapy (NAC) and the impact on surgical outcomes.MethodsWe reviewed all records of cT1-4N1-3M0 breast cancer patients diagnosed between July 2011 and June 2016 who have been registered in the Dutch National Breast Cancer Audit (NBCA) (N = 57.177). The surgical outcomes of 'BCS after NAC′ were compared with 'primary BCS′, using a multivariable logistic regression model.ResultsBetween 2011 and 2016, the use of NAC increased from 9% to 18% and 'BCS after NAC' (N = 4170) increased from 43% to 57%. We observed an involved invasive margin rate ...
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Baek Kim
Publication date: November 2018Source: European Journal of Surgical Oncology, Volume 44, Issue 11Author(s): Baek Kim, Diana Baxter, Andrew Hanby, Eldo Verghese, Andrew Sims, Thomas Hughes
AbstractWorldwide, breast conservation has become increasingly accepted as the surgical management of breast cancer in clinical practice. Cancer care in India is also evolving tremendously with many cancer treatment centres following evidence-based practice hence the rates of breast conservation are expected to increase. Here, we are reporting the rate of breast-conserving surgery (BCS) at our centre. A retrospective study of 401 patients who underwent breast cancer surgery at a tertiary care centre in South India from January 2015 to August 2017 were analysed to study the rate of BCS. All early breast cancers (EBC) were o...
ConclusionsHigh pre-NAC TIL levels were significantly predictive of pCR in BC, and can act as a surrogate marker for predicting therapeutic effects of a TCHP regimen for HER2-positive BC. Post-NAC TILs in residual disease were a new prognostic marker of risk stratification for long-term survival.
CONCLUSION: Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with biopsy-proven node-positive breast cancer is accurate and reliable, but requires careful patient selection and optimal surgical techniques. PMID: 30311642 [PubMed - in process]
In conclusion, the concurrent use of trastuzumab and anthracycline-based NAC for certain HER2-positive locally advanced breast cancers significantly improves the pCR rates without obvious increases in the cardiotoxicity. PMID: 30310287 [PubMed]
Conclusion.These data support the use of fixed‐dose H SC as an adjuvant therapy in HER2‐positive EBC and confirm the comparable safety profile of H SC in patients with low body weight or of Asian origin versus the overall population in SafeHer. ClinicalTrials.gov: NCT01566721.Implications for Practice.The safety profile of fixed‐dose subcutaneous trastuzumab (H SC) was comparable between patients in the lowest bodyweight subgroup and the overall patient population, and also between patients of Asian origin (of whom a higher proportion often fall within the lower bodyweight quartiles) and the overall population. The s...
BJS,Volume 105, Issue 12, Page 1541-1552, November 2018.